checkAd

     496  0 Kommentare Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi's European generics business - Seite 2



    The transaction is expected to close by the end of 2018, subject to finalization of definitive agreements, completion of the appropriate social processes and approval of relevant regulatory authorities. This process will be conducted in full respect of social dialogue with Sanofi employee representatives.




    (1) 1,919 million euros Entreprise Value

    About Zentiva

    Zentiva is an agile healthcare player providing reliable access across Europe to a broad generics portfolio covering a multitude of therapeutic areas. Headquartered in Prague, Zentiva reaches over 40 million patients in 25 European countries, operating throughout a large marketplace with attractive levels of both short- and midterm growth outlook. Zentiva stands apart with the expertise and agility to tailor customer-centric solutions in the three European generics market archetypes (pharmacy, physician and tender/wholesaler). Zentiva's integrated value chain and pan-European commercial footprint makes it one of the largest generics players in Europe. Operating to the highest quality and safety standards, Zentiva's flexible manufacturing facilities in Prague and Bucharest work with partners to produce and distribute more than 350 million packs each year.


    About Advent International


    Founded in 1984, Advent International is one of the largest and most experienced global private equity investors. The firm has invested in over 330 private equity transactions in 40 countries and as of December 31, 2017, it had €35 billion in assets under management. With offices on four continents, Advent has established a globally integrated team of over 190 investment professionals across North America, Europe, Latin America and Asia. The firm focuses on investments in five core sectors, including business and financial services; healthcare; industrial; retail, consumer and leisure; and technology, media and telecom. After more than 30 years dedicated to international investing, Advent remains committed to partnering with management teams to deliver sustained revenue and earnings growth for its portfolio companies.
    Seite 2 von 4



    Diskutieren Sie über die enthaltenen Werte



    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi's European generics business - Seite 2   Press ReleaseSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi's European generics business Advent to invest in Zentiva to create a new, independent European …

    Schreibe Deinen Kommentar

    Disclaimer